Treating Rheumatoid Arthritis with Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs)
- Health Communicator
- Jun 22
- 7 min read
Updated: Sep 3
In 2022, the European Alliance of Associations for Rheumatology (EULAR) updated its recommendations for the treatment of rheumatoid arthritis (RA), placing strong emphasis on safety, efficacy, and the rational use of conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic DMARDs (tsDMARDs, including JAK inhibitors). These updated guidelines integrate the latest scientific evidence and clinical experience to support optimal care for patients living with RA. They are the result of a consensus among a global panel of leading rheumatologists and patient representatives.
AUDIO:
Core Principles
Effective management of rheumatoid arthritis requires a comprehensive and precise treatment approach—one that places equal importance on medical expertise and the informed preferences of the patient. The latest EULAR guidelines highlight shared decision-making between the patient and the rheumatologist as a fundamental principle. This collaborative process is vital, as it considers not only clinical data and evidence-based standards, but also each patient’s lifestyle, personal values, and individual goals. As such, it received the highest possible level of agreement among the experts involved (LoA 10/10).
